Brief: Resverlogix Announces Topline Results In Betonmace Phase 3 Epigenetics Trial
30/09/2019 12:37
Sept 30 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX ANNOUNCES TOPLINE RESULTS IN BETONMACE PHASE 3
EPIGENETICS TRIAL
* RESVERLOGIX CORP - BETONMACE DID NOT MEET PRIMARY ENDPOINT
* RESVERLOGIX CORP - BETONMACE DID NOT MEET PRIMARY ENDPOINT
* RESVERLOGIX CORP - FULL STUDY RESULTS WILL BE PRESENTED
DURING A
LATE-BREAKING SCIENCE SESSION AT AHA 2019
* RESVERLOGIX CORP - APABETALONE DEMONSTRATED TOLERABILITY
AND
SAFETY
* RESVERLOGIX CORP - APABETALONE DEVELOPMENT TO CONTINUE TO
BE
ADVANCED BY COMPANY BASED ON BETONMACE RESULTS
Source text for Eikon: ID:nGNX1GmgGD
Further company coverage: RVX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment